Transforming diagnostic standards and drug development for
Nonalcoholic Steatohepatitis (NASH) with AI-based digital pathology
Who We Are
Founder of an AI-based digital pathology solution that
aids NASH clinical trials towards optimal outcomes
Bridging Researchand Drug Discovery
Working hand-in-hand with our collaborators to accelerate clinical research
and drug development efforts with unrivalled accuracy and sensitivity
NASH Highlights
Catch up on the latest medical advancements and research discoveries on Nonalcoholic Steatohepatitis (NASH) taking place across the globe.
About Us
We are committed towards enhancing the diagnosis of chronic liver conditions like nonalcoholic steatohepatitis (NASH), and accelerating the development of effective treatments.
Revolutionizing tissue assessment with Second Harmonic Generation (SHG) and Two-Photon Excitation (TPE) to provide quantitative, objective and accurate data.
We have been recognised with several industry-renowned awards for our efforts and accomplishments in the core areas of our business, particularly medical technology and product innovation.
We are committed towards building strong and mutually rewarding partnerships with world-renowned medical, academic and research institutions as well as market leaders in the Life Sciences and Healthcare sectors.
Publications & Presentations
Follow up on the journal publications and presentations by HistoIndex and our partners that have graced the platforms of globally renowned industry conferences.
Webinars & Podcasts
We bring you the latest discussions on AI digital pathology by Key Opinion Leaders in NASH. Listen to our webinars and podcasts right here.
Our site uses cookies or similar technologies to recognise your repeated visits and preferences for us to deliver an optimal browsing experience. Please remember to read our privacy statement.
By clicking on "I Accept" or "X" to continue your browsing on this site, you consent to the use of the cookies. To find out how you can disable cookies on your device, please click here.
